Navigation Links
Roche 454 Life Sciences and SoftGenetics Sign Co-Promotion Agreement for Next-Gen Sequencing Software Tools

BRANFORD, Connecticut and STATE COLLEGE, Pennsylvania, May 9, 2012 /PRNewswire/ --

454 Life Sciences, a Roche Company, and SoftGenetics announced today that the two firms have entered into a co-promotion agreement designed to provide users of 454 Sequencing Systems the broad range of next-generation sequencing data analysis options provided by SoftGenetics NextGENe® software.

NextGENe® software is a free standing biologist-friendly software multi-package that is fully compatibility with 454 Sequencing data for a wide variety of applications, including targeted amplicon resequencing, exome sequencing, transcriptome sequencing, forensic profiling and more. The software package provides additional options for users of 454 Sequencing Systems, in addition to the extensive GS Data Analysis Software suite provided with the platforms.

"This agreement permits both 454 and SoftGenetics the opportunity to more fully understand and address the rapidly changing needs of the NGS marketplace," states SoftGenetics co-founder John Fosnacht. "SoftGenetics welcomes the opportunity to work closely with our colleagues at 454 Life Sciences to provide our mutual customers with integrated sequencing and analysis systems that not only delivers the required quality and sensitivity, but also the efficiency needed in today's scientific and economic environments."

SoftGenetics offers 30-day trials and no cost web-based training on its genetic analysis software packages. Interested parties may request the software on the company website at or via email at

About Roche

Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world's largest biotech company with truly differentiated medicines in oncology, virology, inflammation, metabolism and CNS. Roche is also the world leader in in-vitro diagnostics, tissue-based cancer diagnostics and a pioneer in diabetes management. Roche's personalized healthcare strategy aims at providing medicines and diagnostic tools that enable tangible improvements in the health, quality of life and survival of patients. In 2011, Roche had over 80,000 employees worldwide and invested over 8 billion Swiss francs in R&D. The Group posted sales of 42.5 billion Swiss francs. Genentech, United States, is a wholly owned member of the Roche Group. Roche has a majority stake in

Chugai Pharmaceutical, Japan. For more information:

About SoftGenetics

SoftGenetics, LLC specializes in the development of genetic analysis tools for both research and diagnostic applications. Hallmarks of SoftGenetics software tools are advanced technologies, providing exceptional accuracy, and sensitivity in an easy to use Windows® user interface.

For life science research only. Not for use in diagnostic procedures.

454, 454 LIFE SCIENCES, and 454 SEQUENCING, and are trademarks of Roche.

The name "SoftGenetics," the SoftGenetics logo, NextGENe, and the NextGENe Condensation Tool are trademarks or registered trademarks of SoftGenetics, LLC.

All other product names and trademarks are the property of their respective owners.

For further information please contact:
Roche Diagnostics
Dr. Burkhard Ziebolz
Phone: +49-8856-604830

454 Life Sciences Corporation, a Roche Company
Katie Montgomery
Phone: +1-203-871-2300

John Fosnacht
Phone: +1-814-237-9340

SOURCE Roche Diagnostics GmbH
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Roche Launches 454 Sequencing Assays for High Sensitivity Genetic Variant Detection in Leukemia Samples to Drive Blood Cancer Research Worldwide
2. 2 for 1: Simultaneous size and electrochemical measurement of nanomaterials
3. Kitty Castellini Wins Roche Diabetes Cares Diabetes Heroes Torchbearer Challenge
4. Roche Signs Agreement with PTC Therapeutics to Advance Treatment for Spinal Muscular Atrophy (SMA)
5. Roche NimbleGen and BGI Develop Advanced MHC Region Capture Technology for Human Disease and Biomedical Research
6. Electrochemistry controlled with a plasma electrode
7. Roche Licenses Nanopore Sequencing Technologies from Arizona State University and Columbia University for Rapid, Affordable DNA Sequencing
8. Roche NimbleGen Announces New Pre-capture Multiplexing for Target Enrichment Technology in Sequencing
9. Roche Researchers Sequence Complete Genome of Cynomolgus Monkey and Develop Novel Gene Expression Microarray for Drug Safety Assessment
10. Roche Submits Acute Hepatitis B Test to FDA for Premarket Approval
11. China Agri-Business Acquired Management and Operation Rights of Shaanxi Qinfeng Agrochemical Inc. in Xian, China
Post Your Comments:
(Date:11/25/2015)... 26, 2015 --> ... 2016 - 2020 report analyzes that automating biobanking ... quality in long-term samples, minimizing manual errors, improving ... minimizes manual errors such as mislabeling or inaccurate ... it plays a vital role in blood fractionation, ...
(Date:11/25/2015)... , November 25, 2015 2 ... première fois les différences entre les souches bactériennes ... celles des êtres humains . Ces recherches ... et envisager la prise en charge efficace de ... diagnostiqués chez les chats .    --> ...
(Date:11/25/2015)... HOLLISTON, Mass. , Nov. 25, 2015 ... a biotechnology company developing bioengineered organ implants for life-threatening ... will present at the LD Micro "Main Event" investor ... PT. The presentation will be webcast live and posted ... also be available at the conference for one-on-one meetings ...
(Date:11/25/2015)... QUEBEC CITY , Nov. 25, 2015 /PRNewswire/ ... "Company"), affirms that its business and prospects remain ... , Zoptrex™ (zoptarelin doxorubicin) recently received DSMB ... program to completion following review of the final ... met Phase 2 Primary Endpoint in men with ...
Breaking Biology Technology:
(Date:11/17/2015)... SOUTH EASTON, Mass. , Nov. 17, 2015 /PRNewswire/ ... "Company"), a leader in the development and sale of ... to the worldwide life sciences industry, today announced it ... closing of its $5 million Private Placement (the "Offering"), ... Offering to $4,025,000.  One or more additional closings are ...
(Date:11/12/2015)... , Nov. 12, 2015  Arxspan has ... of MIT and Harvard for use of its ... information management tools. The partnership will support the ... biological and chemical research information internally and with ... be used for managing the Institute,s electronic laboratory ...
(Date:11/10/2015)...  In this report, the biomarkers market ... type, application, disease indication, and geography. The ... consumables, services, software. The type segments included ... biomarkers, and validation biomarkers. The applications segments ... drug discovery and development, personalized medicine, disease ...
Breaking Biology News(10 mins):